Health
Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit
ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and Activity Improvements in the Treated Patients versus Placebo SOLANA BEACH, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living w
About this update from Artelo Biosciences, Inc.
[{"type":"image","alt":"Artelo Biosciences","displaySize":"","headline":null,"caption":"Artelo Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":183,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/0fcfe43e16f7cfc8e2a0ef70f1c6364e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dtRWcM_YXYcz7bexobLzxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0fcfe43e16f7cfc8e2a0ef70f1c6364e","width":183,"height":80}},"lazy":false},{"type":"text","content":"ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ","length":148,"tagName":"p"},{"type":"text","content":"ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and Activity Improvements in the Treated Patients versus Placebo","length":125,"tagName":"p"},{"type":"text","content":"SOLANA BEACH, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences, is presenting expanded data from Artelo’s lead Fatty Acid Binding Protein 5 (FABP5) inhibitor, ART26.12, Single Ascending Dose (SAD) Study at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit, taking place October 15–16, 2025, in Boston, Massachusetts. In addition, Professor O’Sullivan will be giving additional insights on ART27.13 development progress in cancer-related anorexia with interim data from the Phase 2 portion of the Cancer Appetite Recovery Study (CAReS).","length":904,"tagName":"p"},{"type":"text","content":"During the presentation titled Exploring the Clinical Development of the Fatty Acid Binding Protein 5 (FABP5) Inhibitor ART26.12, Professor O’Sullivan plans to share findings from the Company’s SAD study and preliminary food effect investigation with ART26.12, which evaluated the safety, tolerability, and pharmacokinetics of its FABP5 inhibitor in healthy volunteers. The SAD study demonstrated that ART26.12 at single doses up to 1050 milligrams was safe and well tolerated. Importantly, AR...